Drug Profile
SAR 439459
Alternative Names: Anti-TGFb SAR-439459; Anti-transforming Growth Factor-beta mAb SAR439459; SAR-439459Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Sanofi
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Transforming growth factor beta inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Osteogenesis imperfecta
- Discontinued Solid tumours
Most Recent Events
- 10 Aug 2023 SAR 439459 is still in phase I clinical trials for Osteogenesis imperfecta in USA (IV) (Sanofi pipeline, June 2023)
- 10 Feb 2023 Discontinued - Phase-I for Osteogenesis imperfecta in USA (IV) (Sanofi pipeline; February 2023 )
- 03 Jun 2022 Efficacy and adverse events data from a phase I/Ib trial in Solid tumours presented at the 58th Annual Meeting of the American Society of Clinical Oncology (ASCO-2022)